Millennium reports 5.1% stake in Protara Therapeutics
Protara Therapeutics Schedule 13G: Millennium group reports shared ownership of 2,759,231 common shares (5.1%).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Protara Therapeutics Schedule 13G: Millennium group reports shared ownership of 2,759,231 common shares (5.1%). The filing states that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander share voting and dispositive power over 2,759,231 shares of Protara Therapeutics common stock as of 02/25/2026. A Joint Filing Agreement dated 02/27/2026 is attached, and signatures by representatives, including Israel A. Englander, are included.
Insights
Shared control of 5.1% stake reported by Millennium and Mr. Englander.
The schedule lists 2,759,231 shares and 5.1% of the class as held with shared voting and dispositive power by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander as of 02/25/2026. The filing attaches a Joint Filing Agreement dated 02/27/2026.
Because the filing reports a group with shared control, subsequent trading or additional disclosures by the group could affect public float dynamics. Future filings may disclose changes in the group’s holdings or voting arrangements.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Millennium report in Protara Therapeutics (TARA)?
Who are the filers on the Schedule 13G for TARA?
Does the Schedule 13G include an agreement among the filers?
What is the reporting date for the ownership figures in this filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.